Cooper Financial Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6,524
Closed -$240K 475
2026
Q1
$240K Buy
6,524
+2,272
+53% +$108K 0.02% 371
2025
Q4
$216K Sell
4,252
-2,366
-36% -$121K 0.02% 360
2025
Q3
$367K Buy
+6,618
New +$387K 0.04% 275
2025
Q2
Sell
-11,367
Closed -$789K 397
2025
Q1
$789K Buy
11,367
+295
+3% +$24.4K 0.1% 172
2024
Q4
$952K Buy
11,072
+593
+6% +$64.1K 0.11% 149
2024
Q3
$1.25M Buy
10,479
+507
+5% +$67.6K 0.16% 108
2024
Q2
$1.42M Sell
9,972
-1,470
-13% -$195K 0.21% 88
2024
Q1
$1.47M Buy
11,442
+211
+2% +$25.1K 0.24% 85
2023
Q4
$1.16M Buy
11,231
+89
+0.8% +$8.8K 0.21% 93
2023
Q3
$1.01M Buy
11,142
+752
+7% +$66.2K 0.24% 100
2023
Q2
$841K Buy
10,390
+6,306
+154% +$515K 0.21% 114
2023
Q1
$325K Buy
+4,084
New +$290K 0.09% 234

Other funds holding NVO

Cooper Financial Group's NVO Position: Q2 2026 in Review

Cooper Financial Group sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 6,524 shares — an estimated $240K sold.

Cooper Financial Group first reported a position in NVO in Q1 2023 and held it in 12 quarters. The position peaked at $1.47M in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cooper Financial Group reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Cooper Financial Group sold 6,524 Novo Nordisk shares in Q2 2026, an estimated $240K.
  • Cooper Financial Group first reported a position in Novo Nordisk in Q1 2023 and held it in 12 quarters.
  • Cooper Financial Group's Novo Nordisk position peaked at $1.47M in Q1 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cooper Financial Group's 13F filing for Q2 2026, filed 8 Jul 2026.